Notably, we focused on CEA, which is highly expressed in pancreatic cancer, as the target antigen, and analyzed the efficacy of anti-CEA-CAR-T therapy in PDAC based on CEA expression levels [12]. Here, CEACAM5 is linked to pancreatic neoplasm.